OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

This study is for women with ovarian cancer that has returned after initial treatment, but whose cancer still responds well to platinum-based chemotherapy. This type of cancer is called 'platinum-sensitive recurrent ovarian cancer'. Even after chemotherapy, there isn't a proven maintenance treatment that can reliably keep the cancer away for longer periods, especially after having received certain other medications like bevacizumab and PARP inhibitors. This means there's a real need for new approaches to help patients stay well for longer after their chemotherapy.

The researchers are testing a new vaccine called OSE2101. This vaccine is designed to help your body's immune system recognise and fight cancer cells. They believe that if the immune system can be made stronger to fight the cancer, it might delay the cancer from returning. The study will also look at combining this vaccine with another drug called Pembrolizumab (Keytruda), which is an immunotherapy that works to boost your immune system's ability to attack cancer. The idea is that these two treatments together might be even more effective.

Patients taking part in this study will be split into three groups by chance (like drawing names from a hat): one group will receive the OSE2101 vaccine, another group will receive the OSE2101 vaccine plus Pembrolizumab, and the third group will receive what is called Best Supportive Care. Best Supportive Care means you will receive the usual care to manage your symptoms and maintain your quality of life, without receiving the experimental drugs. The study will then compare these groups to see if the new treatments can help patients live longer without their cancer getting worse, helping to find better long-term options for women with this condition.